Recombinant Mouse Gzmc Protein ，His & Myc

Gzmc, or Granzyme M, is a serine protease predominantly expressed by cytotoxic T lymphocytes and natural killer (NK) cells, playing a crucial role in the immune response against tumor cells and virus-infected cells. Research on Gzmc has gained significant attention due to its unique mechanisms of action, which differ from other granzymes, such as Granzyme A and Granzyme B. Unlike these granzymes, which primarily induce apoptosis through DNA fragmentation, Gzmc has been shown to target multiple cellular pathways, leading to varied effects, including promoting cell death and influencing inflammation. The therapeutic potential of Gzmc, particularly in cancer immunotherapy and infectious diseases, is a focal point of study, as understanding its structure and function can lead to novel treatment strategies. Recombinant Gzmc proteins are being explored for their ability to enhance immune responses and selectively eliminate malignant cells. Investigating the biochemical properties of Gzmc, including its substrate specificity and interactions with cellular components, is essential for developing effective approaches that harness its immune-modulating capabilities. Overall, the study of Gzmc and its recombinant forms is positioned at the intersection of immunology and therapeutic development, potentially paving the way for innovative treatments in oncology and other diseases where the immune system's role is crucial.